Takeda Akihiro, Koike Wataru
Department of Obstetrics and Gynecology, Gifu Prefectural Tajimi Hospital, 5-161 Maebata-cho, Tajimi, Gifu, 507-8522, Japan.
Department of Radiology, Gifu Prefectural Tajimi Hospital, 5-161 Maebata-cho, Tajimi, Gifu, 507-8522, Japan.
Arch Gynecol Obstet. 2017 Dec;296(6):1189-1198. doi: 10.1007/s00404-017-4528-0. Epub 2017 Oct 4.
To report our experience on the value of transcatheter arterial embolization (TAE) or transcatheter arterial chemoembolization (TACE) for the uterus-preserving management of retained placenta accreta with marked vascularity after abortion or delivery.
Thirty-eight consecutive women with retained placenta accreta were retrospectively analyzed over a 5-year period. When elevated levels of serum β-hCG (> 25 mIU/mL) were detected, TACE with dactinomycin was chosen for devascularization along with cytotoxic effects on active trophoblasts; in contrast, if the serum β-hCG level was low (≤ 25 mIU/mL), TAE was chosen. After confirming devascularization, the additional need for hysteroscopic resection and systemic methotrexate administration was individually determined.
The most frequent sign and symptom in the abortion group was significant hemorrhaging, while a hypervascular mass detected at a regular check-up was the most frequent in the delivery group. The median time elapsed between abortion and endovascular management was 36 days, and the median time elapsed after delivery was 31.5 days. TACE was performed more frequently than TAE in the abortion group, while TAE was the more frequent procedure in the delivery group. In 10 and 11 cases, after abortion and delivery, respectively, hysteroscopic resection was performed. Systemic methotrexate administration was additionally done in three and one cases after abortion and delivery, respectively. Uterine preservation was achieved in all cases.
This case series emphasizes that endovascular embolization is an effective key intervention with or without additional therapies for uterus-preserving management of retained placenta accreta with marked vascularity after abortion or delivery.
报告我们关于经导管动脉栓塞术(TAE)或经导管动脉化疗栓塞术(TACE)在流产或分娩后保留的伴有明显血管增生的胎盘植入保留子宫治疗中的应用经验。
回顾性分析了连续5年收治的38例保留胎盘植入患者。当检测到血清β - hCG水平升高(> 25 mIU/mL)时,选择放线菌素进行TACE以实现血管去功能化,并对活跃的滋养细胞产生细胞毒性作用;相反,如果血清β - hCG水平较低(≤ 25 mIU/mL),则选择TAE。在确认血管去功能化后,单独确定是否需要额外进行宫腔镜切除和全身应用甲氨蝶呤。
流产组最常见的体征和症状是大量出血,而在分娩组定期检查时发现的高血管团块最为常见。流产与血管内治疗之间的中位时间间隔为36天,分娩后的中位时间间隔为31.5天。流产组中TACE的实施频率高于TAE,而分娩组中TAE是更常用的方法。流产后和分娩后分别有10例和11例进行了宫腔镜切除。流产后和分娩后分别有3例和1例额外进行了全身甲氨蝶呤治疗。所有病例均成功保留了子宫。
本病例系列强调,血管内栓塞术是流产或分娩后保留的伴有明显血管增生的胎盘植入保留子宫治疗的有效关键干预措施,无论是否联合其他治疗。